Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now

Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now

Abstract Human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) is a highly aggressive subtype associated with poor prognosis. The advent of HER2-targeted drugs, including monoclonal antibodies, tyrosine-kinase inhibitors (TKIs) and antibody–drug conjugates, has yielded improved...

Full description

Bibliographic Details
Main Authors: Xiaowei Qi, Qiyun Shi, Juncheng Xuhong, Yi Zhang, Jun Jiang
Format: Article
Language:English
Published: BMC 2023-10-01
Series:Breast Cancer Research
Subjects:
Pyrotinib
HER-2 positive
Breast cancer
Targeted therapy
Tyrosine-kinase inhibitor
Online Access:https://doi.org/10.1186/s13058-023-01694-5

Internet

https://doi.org/10.1186/s13058-023-01694-5

Similar Items